Abstract
Aims/hypothesis
Microvascular endothelial hyperpermeability, mainly caused by claudin-5 deficiency, is the initial pathological change that occurs in diabetes-associated cardiovascular disease. The ketone body β-hydroxybutyrate (BHB) exerts unique beneficial effects on the cardiovascular system, but the involvement of BHB in promoting the generation of claudin-5 to attenuate cardiac microvascular hyperpermeability in diabetes is poorly understood.
Methods
The effects of BHB on cardiac microvascular endothelial hyperpermeability and claudin-5 generation were evaluated in rats with streptozotocin-induced diabetes and in high glucose (HG)-stimulated human cardiac microvascular endothelial cells (HCMECs). To explore the underlying mechanisms, we also measured β-catenin nuclear translocation, binding of β-catenin, histone deacetylase (HDAC)1, HDAC3 and p300 to the Claudin-5 (also known as CLDN5) promoter, interaction between HDAC3 and β-catenin, and histone acetylation in the Claudin-5 promoter.
Results
We found that 10 weeks of BHB treatment promoted claudin-5 generation and antagonised cardiac microvascular endothelial hyperpermeability in rat models of diabetes. Meanwhile, BHB promoted claudin-5 generation and inhibited paracellular permeability in HG-stimulated HCMECs. Specifically, BHB (2 mmol/l) inhibited HG-induced HDAC3 from binding to the Claudin-5 promoter, although nuclear translocation or promoter binding of β-catenin did not change with BHB treatment. In addition, BHB prevented the binding and co-localisation of HDAC3 to β-catenin in HG-stimulated HCMECs. Furthermore, using mass spectrometry, acetylated H3K14 (H3K14ac) in the Claudin-5 promoter following BHB treatment was identified, regardless of whether cells were stimulated by HG or not. Although reduced levels of acetylated H3K9 in the Claudin-5 promoter were found following HG stimulation, increased H3K14ac was specifically associated with BHB treatment.
Conclusions/interpretation
BHB inhibited HDAC3 and caused acetylation of H3K14 in the Claudin-5 promoter, thereby promoting claudin-5 generation and antagonising diabetes-associated cardiac microvascular hyperpermeability.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Cardiovascular disease is the principal cause of death and morbidity among people with diabetes, who have a two- to fourfold increased cardiovascular risk compared with adults without diabetes [1]. The cardiac microvasculature refers to vessels <150 μm in diameter, which provide nutrients and remove metabolic byproducts within the heart tissue [2]. Endothelial dysfunction is the initial factor and early pathological manifestation leading to diabetic microvascular diseases, which are believed to play important pathophysiological roles in the development of heart failure [3, 4].
Endothelial tight junctions control paracellular permeability, serving as an important barrier to maintain vascular homeostasis in blood vessels [5]. Disruption of tight junctions is a hallmark event in endothelial barrier dysfunction, leading to paracellular hyperpermeability in diabetes [6]. Cardiac microvascular hyperpermeability leads to leakage of pathological factors that trigger subsequent fibrosis or cardiomyocyte damage [6, 7]. However, the underlying mechanism of cardiac microvascular hyperpermeability in diabetes has not been clarified and there is no effective therapy.
Claudin-5 is considered the main component of endothelial tight junctions, where it plays a crucial role in the control of endothelial permeability [8]. In diabetes, claudin-5 dysfunction is a major contributor to microvascular hyperpermeability [9]. Our previous study showed that claudin-5 expression was suppressed in high glucose (HG)-stimulated human cardiac microvascular endothelial cells (HCMECs) [10]. The Wnt/β-catenin signalling pathway is essential for the maintenance of endothelial homeostasis [11]. Following the binding of Wnt ligand to its receptor, β-catenin is translocated to the nucleus to regulate the transcription of target genes, including Claudin-5 (also known as CLDN5) [12]. Additionally, histone modification, particularly acetylation of lysine residues, acts as an on/off switch for gene transactivation [13, 14]. Acetyltransferase and histone deacetylases (HDACs) are ‘writers’ and ‘erasers’ of histone acetylation, respectively, tightly controlling gene transcription. As a key transcriptional co-activator, acetyltransferase p300 is involved in the transactivation of pathological genes in cardiovascular diseases [13]. Relating to acetyltransferase, members of the HDAC family have different roles, and type 1 HDACs, particularly HDAC3, are believed to be the main contributors to cardiovascular disease in diabetes [14, 15]. However, it is unclear whether changes in β-catenin or its recruitment with the co-factors HDACs or p300, lead to suppressed claudin-5 transcription and cardiac microvascular hyperpermeability in diabetes.
In situations of insufficient glucose supply, such as starvation, ketone bodies are generated to provide energy [16]. Although a sharp increase in ketone bodies can cause ketoacidosis in individuals with diabetes, moderate increases (<10 mmol/l) have been reported to have important protective roles [17]. The main component of ketone bodies, β-hydroxybutyrate (BHB), has been recently characterised as a biologically active molecule with multiple beneficial roles [18]. Besides supplying energy, BHB has various cardiovascular protective effects that are especially strong in endothelial cells [19,20,21]. We have published a series of studies in rat models of diabetes, demonstrating that BHB treatment elevated the expression of vascular endothelial growth factor to alleviate aortic endothelial injury, and promoted the generation of matrix metalloproteinase-2 to antagonise glomerulosclerosis [22, 23]. A broad spectrum of targets has been proposed for the protective effects of BHB [18]. BHB has been reported to bind to a membrane receptor, interact with key functional proteins or inhibit the nucleotide-binding domain leucine-rich repeat (NLR) and pyrin domain containing receptor 3 (NLRP3) inflammasome [20, 24, 25]. Notably, BHB enters the nucleus and inhibits type 1 HDACs to elevate histone acetylation and activate the expression of protective genes [26]. Although BHB exhibits conspicuous cardiovascular protective effects, there is no report of the effects of BHB on β-catenin, and no one has investigated whether it inhibits HDACs to activate Claudin-5 transcription and antagonise cardiac microvascular hyperpermeability in diabetes.
In this study, we aimed to evaluate BHB-induced claudin-5 generation and antagonism of cardiac microvascular hyperpermeability in rat models of diabetes. We also aimed to verify the effects of BHB on claudin-5 generation and paracellular hyperpermeability in HG-stimulated HCMECs. The mechanism by which BHB promotes claudin-5 generation was explored through measurements of β-catenin nuclear translocation, binding of β-catenin, HDAC1, HDAC3 and p300 to the Claudin-5 promoter, interaction between β-catenin and HDAC3, and histone acetylation in the Claudin-5 promoter in HG-stimulated HCMECs.
Methods
Animal experiments
Animal care and use were performed in accordance with the procedures outlined in the National Institutes of Health Guidelines and the experimental protocol was approved by the Institutional Ethics Committee of Hebei Medical University (Hebei, People’s Republic of China). Seventy healthy male Sprague Dawley rats (210.38 ± 26.25 g; 6 weeks old) and their standard chow were provided by the Department of Experimental Animals of Hebei Medical University. Rats were maintained in a controlled environment (12 h dark–light cycles; 22–24°C; humidity 50–60%) with free access to water and chow. Rats were randomly divided into five groups: diabetes mellitus (‘DM’; n = 15); DM+low concentration BHB (‘BHB1’; n = 15); DM+intermediate concentration BHB (‘BHB2’; n = 15); DM+high concentration BHB (‘BHB3’; n = 15); and control (‘Con’; n = 10). The former four DM groups were injected intraperitoneally with streptozotocin (STZ; 40 mg/kg, dissolved in freshly made 0.1 mol/l citrate buffer, pH 4.4, 10 mg/ml) to induce diabetes, as previously reported [27]. Rats in the BHB1, BHB2 and BHB3 groups were injected subcutaneously with 160 mg kg−1 day−1, 200 mg kg−1 day−1 and 240 mg kg−1 day−1 BHB (Sigma, Steinheim, Germany), respectively [22, 23]; rats in the DM and Con groups were administered an equivalent volume of saline (154 mmol/l NaCl). Fasting blood glucose and body weight were measured at 3 days and 10 weeks after diabetes induction. At the end of the experiment, FITC-labelled dextran was used to measure cardiac and mesenteric microvascular endothelial permeability in vivo. After the rats were killed, a segment of heart tissue was collected for H&E staining and claudin-5 immunofluorescence staining, and another segment was used for the detection of claudin-5 mRNA expression and protein content.
Microvascular permeability
FITC-dextran (70 kDa; Sigma-Aldrich, Munich, Germany) was used in the measurement of cardiac microvascular permeability in vivo [28]. Rats were anaesthetised and treated with FITC-dextran (20 mg in 1 ml saline) through caudal vein injection. Thirty min after injection, the animals were killed and heart tissue was taken out and frozen immediately. After being cut, frozen sections were observed and imaged using a fluorescence microscope (IX51; Olympus, Tokyo, Japan). In addition, when the rats were killed, mesentery was taken out immediately for the observation of mesenteric microvessels using a fluorescence microscope.
Cells and treatments
HCMECs without mycoplasma contamination were purchased from ScienCell and cultured in Endothelial Cell Medium (ScienCell, Carlsbad, USA) with 5 mmol/l glucose and 10% (vol./vol.) fetal bovine serum. After the cells were treated with 20 mmol/l, 25 mmol/l, 30 mmol/l and 35 mmol/l HG for 24 h, Claudin-5 mRNA expression and paracellular permeability were measured to verify the optimal HG concentration for claudin-5 suppression and paracellular hyperpermeability. Subsequently, the cells were divided into low glucose (LG, 5 mmol/l), high l-glucose (l-HG; 25 mmol/l), HG (25 mmol/l) and HG+BHB (1 mmol/l, 2 mmol/l, 4 mmol/l) groups. mRNA expression and protein content of claudin-5, as well as paracellular permeability, were measured following 24 h treatment. In addition, the cellular distribution of claudin-5 was detected following 2 mmol/l BHB treatment. Furthermore, the content and nuclear translocation of β-catenin, and the binding of β-catenin, HDAC1, HDAC3 and p300 to the Claudin-5 promoter were measured. The binding and co-localisation of HDAC3 and β-catenin were detected; therefore, associated histone acetylations in the Claudin-5 promoter were analysed.
Paracellular permeability assay
HCMECs were cultured on transwell inserts (Fisher Scientific, Corning, NY, USA) until confluent. Then 70 kDa FITC-dextran (1 mg/ml final concentration) was added to the culture medium in the upper chamber. After 1 h incubation, the concentration of FITC-dextran transferred to the lower chamber was determined using a microplate reader (SpectraMax i3; Molecular Devices, San Jose, CA, USA) with excitation and emission wavelengths of 490 nm and 530 nm, respectively.
Quantitative RT-PCR
mRNA expression of Claudin-5 was quantified by quantitative RT-PCR. Total RNA was isolated using Trizol reagent (Takara, Dalian, China) and reverse transcribed into cDNA using the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Shanghai, China), followed by quantitative real-time PCR amplification using specific primers (see electronic supplementary material [ESM] Table 1). 18S RNA primers were used as an internal standard.
Immunofluorescence
Cellular distribution of claudin-5 and nuclear translocation of β-catenin were detected by immunofluorescence, as previously reported [10]. The primary antibodies used were anti-claudin-5 (1:50 dilution in PBS; catalogue no. BS1069; Bioworlde, Nanjing, China), anti-CD31 (1:50 dilution in PBS; catalogue no. GB12063; Servicebio, Wuhan, China) or anti-β-catenin (1:50 dilution in PBS; catalogue no. sc-7963; Santa Cruz, Starr County, TX, USA), and the corresponding secondary antibodies were FITC- or tetramethylrhodamine (TRITC)-conjugated (1:20 dilution in PBS; catalogue no. ZF0312 or ZF0316; Zhongshan, Beijing, China), with DAPI being used for nucleus staining. Images were observed under a fluorescence microscope (IX51; Olympus). To get exact results, controls (PBS instead of the primary or secondary antibody) were designed to eliminate background noise.
DNA pull-down
Contents of β-catenin, HDAC1, HDAC3, p300, acetylated H3K9 (H3K9ac) and acetylated H3K14 (H3K14ac) bound to the Claudin-5 promoter were measured by DNA pull-down assay. Cells were collected and nuclear proteins were fractionated using a nuclear extraction kit (BestBio, Shanghai, China). After protein concentration was determined, we performed a DNA affinity precipitation assay. Oligonucleotides that contained biotin on the 5′ end of each strand were used. Sequences of oligonucleotides for the β-catenin binding site and the mutant binding site are presented in ESM Table 2. Each pair of oligonucleotides was annealed according to standard protocols. Nuclear protein extracts (200 μg) were precleared with ImmunoPure streptavidin-agarose beads (20 μl/sample; Thermo Fisher Scientific, Waltham, MA, USA). After centrifugation, the supernatant was incubated with 4 μg of biotinylated double-stranded oligonucleotides overnight. Streptavidin-agarose beads (20 μl) were added and incubated for 4 h, and the protein–DNA–streptavidin–agarose complex was subjected to western blotting or mass spectrometry. Mass spectrometry was performed by Jingjie PTM Biolab (Hangzhou, China).
Chromatin immunoprecipitation
The binding of β-catenin to the Claudin-5 promoter was analysed by chromatin immunoprecipitation (ChIP), performed as previously described [27]. In brief, anti-β-catenin antibody (4 μg) or control rabbit IgG (both Santa Cruz) were added to the sonicated lysate, and then protein G agarose beads (20 μl/sample; Santa Cruz) were used for immunoprecipitation. Primers for the predicted β-catenin binding site in the human Claudin-5 promoter (Gene ID: 7122) were as follows: β-catenin–Claudin-5 (forward) 5′-GCCCTGTCCAATGGAAC-3′, β-catenin–Claudin-5 (reverse) 5′-CATTTCTCGAAAGGTCCAC-3′; with a 235 bp product.
Co-immunoprecipitation
Binding of HDAC1, HDAC3 and p300 to β-catenin was analysed by co-immunoprecipitation (Co-IP) assay using previously described methods [27]. In brief, nuclear extracts were re-suspended in ice-cold immunoprecipitation buffer, reacted with anti-β-catenin antibody (2 μg; Santa Cruz) and incubated with protein G agarose (20 μl/sample; Santa Cruz) overnight. Co-immunoprecipitated HDAC1, HDAC3 and p300 was detected by western blotting. Conversely, anti-HDAC3 antibody (2 μg; catalogue no. ab137704; Abcam, Shanghai, China) was used and co-immunoprecipitated β-catenin was detected by western blotting. Nuclear β-catenin, HDAC1, HDAC3 or p300 was used as the input and β-actin as a loading control.
Western blotting
Protein levels of claudin-5, β-catenin, HDAC1, HDAC3, p300, H3K9ac and H3K14ac were detected by western blotting, using a previously described protocol [10, 27]. The antibodies used were: anti-claudin-5 (1:200 dilution in PBS; Bioworlde), anti-β-catenin (1:200 dilution in PBS; Santa Cruz), anti-HDAC1 (1:1000 dilution in PBS; catalogue no. ab7028; Abcam), anti-HDAC3 (1:1000 dilution in PBS; Abcam), anti-p300 (1:500 dilution in PBS; catalogue no. NB500–161; Novus Biologicals, Littleton, CO, USA), anti-H3K9ac (1:500 dilution in PBS; catalogue no. 9649S; CST, Shanghai, China), anti-H3K14ac (1:500 dilution in PBS; catalogue no. 7627S; CST), anti-H3 (1:1000 dilution in PBS; catalogue no. 4499S; CST) and anti-β-actin (1:2000 dilution in PBS; catalogue no. D110001; Sangon Biotech, Shanghai, China). Band intensity was quantified by Quantity One v4.6.2 software (Bio-Rad, Shanghai, China) and calculated as indicated.
Confocal microscopy
Co-localisation of HDAC3 and β-catenin was measured by confocal detection, as previously described [27]. The primary antibodies used were anti-HDAC3 (1:50 dilution; Abcam) and anti-β-catenin (1:50 dilution in PBS; Santa Cruz), and the secondary antibodies used were FITC- and TRITC-conjugated (1:20 dilution in PBS; catalogue no. ZF0311 and ZF0313; Zhongshan). Images were obtained during the same intervals between samples with a laser confocal scanning microscope (Olympus). To get exact results, controls (PBS instead of the first antibody or the second antibody) were designed to eliminate background noise.
Statistical analysis
Data are presented as means±SD from distinct samples. One-way ANOVA was used to analyse differences among groups, and differences between two groups were evaluated using the least significant difference test (two-tailed). Values of p < 0.05 were considered statistically significant. Experiments were not randomised or blinded. Rats of accidental death or outrageous deviation were excluded for the data statistics of blood glucose and body weight.
Results
BHB antagonised cardiac microvascular hyperpermeability and promoted claudin-5 generation in diabetic rats
First we measured the effects of BHB on blood glucose and body weight in diabetic rats. Compared with the Con group, blood glucose was significantly higher throughout the experiment in the DM group, which was not reduced by BHB treatment (Fig. 1a). A decrease in body weight was observed in the DM group at 10 weeks vs Con, which was not reversed by BHB treatment (Fig. 1b). Typical cardiac microvascular endothelial changes were evaluated by H&E staining (Fig. 1c). Intact endothelium was observed in the Con group, while the endothelium was deteriorating with disordered arrangement of myocardial fibres in the DM group. However, the endothelium exhibited partial deterioration with regularly arranged myocardial fibres in the BHB2 and BHB3 groups.
FITC-dextran was used to measure cardiac microvascular permeability (Fig. 1d). Although not observed in the Con group, FITC fluorescence was distinctive in the DM group, reflecting microvascular hyperpermeability. The fluorescence was dramatically diminished in the BHB groups, particularly the BHB2 group. In addition, FITC fluorescence in mesenteric microvessels provided consistent directly feasible results of microvascular permeability, which showed bright FITC fluorescence in the DM group and obviously weakening of the signal in the BHB groups, especially the BHB2 group (ESM Fig. 1).
These results indicated that BHB could antagonise cardiac microvascular endothelial injury and hyperpermeability in the diabetic rats, without affecting blood glucose.
Next, we evaluated mRNA expression and protein content of claudin-5 (Fig. 2a, b). Compared with the Con group, claudin-5 mRNA expression and protein content were considerably decreased in the DM group, but were significantly elevated in the BHB2 group vs DM. Therefore, cardiac microvascular distribution of claudin-5 was illustrated for BHB2 treatment (Fig. 2c). Immunofluorescence of claudin-5 in the cardiac microvasculature was obviously weakened in the DM group, and was conspicuously reversed in the BHB2 group, consistent with the changes in claudin-5 expression. These results demonstrated that BHB could antagonise cardiac microvascular hyperpermeability and promote claudin-5 generation in diabetic rats.
BHB promoted claudin-5 generation and attenuated paracellular hyperpermeability in HG-stimulated HCMECs
The mRNA expression of Claudin-5 and paracellular permeability were measured to confirm the optimal concentration of HG stimulation for HCMECs (ESM Fig. 2). Compared with the normal glucose (5 mmol/l) group, Claudin-5 mRNA expression decreased and paracellular permeability increased significantly with HG stimulation at 25 mmol/l, 30 mmol/l and 35 mmol/l. The results showed that 25 mmol/l HG was sufficient to suppress Claudin-5 expression and cause paracellular hyperpermeability of HCMECs.
The effects of BHB on claudin-5 generation were examined in HG-stimulated HCMECs. Compared with the LG group, claudin-5 mRNA expression and protein content decreased notably in the HG group, but the decrease was non-significant in the l-HG group (Fig. 3a, b). However, the HG-induced suppression of claudin-5 was reversed with BHB treatment in a concentration-dependent manner, with a significant increase in the 2 mmol/l and 4 mmol/l BHB groups vs HG. Additionally, the immunofluorescence distribution of cellular claudin-5 was distinctly weakened under HG stimulation, but noticeably re-appeared with 2 mmol/l BHB treatment (Fig. 3c).
FITC-dextran was used to measure the paracellular permeability of HCMECs. Compared with the LG group, paracellular permeability increased conspicuously in the HG group. However, this was significantly reduced with the addition of 2 mmol/l and 4 mmol/l BHB to HG treatment, as compared with the HG group (Fig. 3d). These data manifested that BHB could promote claudin-5 generation and attenuate paracellular hyperpermeability in HG-stimulated HCMECs in a concentration-dependent manner.
BHB prevented HDAC3 from binding to the Claudin-5 promoter in HG-stimulated HCMECs
The contents and nuclear translocation of β-catenin, the transcriptional regulator of Claudin-5 expression, were examined. Treatment with HG with or without BHB did not lead to significant changes in either the total or nuclear content of β-catenin in HCMECs (Fig. 4a, b). The results were corroborated by immunofluorescence of β-catenin under treatment with HG with or without 2 mmol/l BHB (Fig. 4c). The predicted β-catenin binding site in the Claudin-5 promoter is illustrated in Fig. 5a. We performed a DNA pull-down assay to analyse the content of β-catenin bound to the Claudin-5 promoter (Fig. 5b). No significant differences were found among the treatment groups for the calculated ratio of pull-down β-catenin to its input. The ChIP assay results confirmed that the level of Claudin-5 promoter bound by β-catenin was similar between the treatment groups (Fig. 5c).
We also examined the content of Claudin-5 promoter-bound HDAC1, HDAC3 and p300 by DNA pull-down assay (Fig. 5d), and the ratios of pull-down HDAC1, HDAC3 and p300 to their inputs were calculated to show relative promoter-bound protein content (Fig. 5e). Compared with the LG group, bound HDAC3 was decreased in the BHB group but increased in the HG group. Furthermore, BHB treatment significantly reduced the HG-induced increase in bound HDAC3, but had no significant effect on bound HDAC1 or p300. These results showed that BHB prevented HDAC3 from binding to the Claudin-5 promoter in HG-stimulated HCMECs, without affecting β-catenin indicators.
BHB inhibited the interaction between HDAC3 and β-catenin in HG-stimulated HCMECs
Next we evaluated the binding of HDAC1, HDAC3 and p300 to β-catenin using Co-IP. For β-catenin immunoprecipitation, the contents of co-immunoprecipitated HDAC1, HDAC3 and p300 were detected (Fig. 6a). The ratios of co-immunoprecipitated HDAC1, HDAC3 and p300 to their respective input values were calculated to show the relative bound content (Fig. 6b). Compared with the LG group, only HDAC3 content increased significantly in the HG group, but this increase was significantly reduced by BHB treatment. In parallel, for HDAC3 immunoprecipitation, the content of co-immunoprecipitated β-catenin was detected and calculated (Fig. 6c, d). Compared with the LG group, β-catenin content increased noticeably in the HG group, but was significantly decreased in the HG+BHB group.
The co-localisation of HDAC3 and β-catenin was also observed by confocal scanning microscopy (Fig. 7). Although no obvious differences were found among the groups in the contents of HDAC3 and β-catenin, there was a distinctive co-localisation of HDAC3 and β-catenin in the HG group. However, the HG-stimulated co-localisation of HDAC3 and β-catenin was overtly inhibited by BHB treatment. These results suggested that BHB inhibited the binding and co-localisation of HDAC3 and β-catenin in HG-stimulated HCMECs.
BHB caused specific increases in H3K14ac in the Claudin-5 promoter
Since BHB inhibited the binding of HDAC3 to both the Claudin-5 promoter and β-catenin, we measured histone acetylation in the promoter-binding site for β-catenin. After DNA pull-down with the Claudin-5 promoter sequence containing the β-catenin binding site, histone acetylations were analysed using mass spectrometry (Fig. 8a). The results identified specific H3K14ac modification in both the BHB and HG+BHB groups.
First, we examined the total content of the identified H3K14ac, as well as general H3K9ac modifications (ESM Fig. 3). Neither H3K14ac nor H3K9ac showed significant differences between the groups. Following this, the contents of H3K14ac and H3K9ac in the Claudin-5 promoter were measured by DNA pull-down assay (Fig. 8b). The ratios of pull-down H3K9ac or H3K14ac to H3 were calculated to show the relative content of each (Fig. 8c). Although no significant difference was observed between the LG and HG groups for H3K14ac, its content increased significantly in the BHB and HG+BHB groups vs LG and HG, respectively. In contrast, compared with that in the LG group, H3K9ac content decreased in the HG group, but was not significantly affected by BHB treatment.
These results confirmed that BHB treatment caused specific increases in H3K14ac in the Claudin-5 promoter, activating claudin-5 transcription.
Discussion
In this study, we found that BHB promoted claudin-5 generation and antagonised cardiac microvascular hyperpermeability in the STZ-induced diabetes rat model. In addition, under HG stimulation, BHB was found to promote claudin-5 generation and attenuated paracellular hyperpermeability in HCMECs in a concentration-dependent manner. Our data also clarified that HG stimulation provoked HDAC3 and reduced H3K9ac in the Claudin-5 promoter to suppress claudin-5 expression. In contrast, BHB treatment inhibited HDAC3 and caused a specific increase in H3K14ac in the Claudin-5 promoter, thereby activating claudin-5 generation.
Endothelial dysfunction is the initial pathological factor in cardiac microvascular diseases, and disruption of tight junctions, a hallmark event of endothelial barrier dysfunction, leads to cardiac microvascular hyperpermeability in individuals with diabetes [29, 30]. Clinical studies have suggested that individuals with microvascular complications are at increased risk of dilated cardiomyopathy, indicating the importance of endothelial hyperpermeability in the pathogenesis of cardiomyopathy [31]. We also observed both mesenteric and cardiac microvascular hyperpermeability, with disorderly arrangement of myocardial fibres being observed in the diabetic rats. Several studies have emphasised the importance of claudin-5 in brain microvascular hyperpermeability, including in diabetic conditions [8, 32]. In addition, in individuals with diabetic macular oedema, inflammation-induced claudin-5 redistribution leads to blood–retinal barrier disruption [9]. Our results confirmed the presence of claudin-5 insufficiency and endothelial hyperpermeability in the cardiac microvasculature under diabetic conditions. However, indicators for β-catenin, the transcriptional regulator of claudin-5, showed minimal changes under HG stimulation in this study.
The acetyltransferase p300 and HDACs are positive and negative controllers of histone acetylation, respectively, comprising an on/off switch for gene transactivation [13,14,15]. p300 may participate in the transactivation of pathological genes in diabetes, and p300 inhibitors have been reported to reverse hypertension-induced cardiac hypertrophy and fibrosis [13, 27]. HDACs play pathogenic and protective roles depending on the disease, and HDAC3 inhibition may have therapeutic potential for cardiovascular diseases [33]. Our results showed that HDAC3 binding to both the Claudin-5 promoter and β-catenin increased significantly under HG stimulation. Additionally, the critical histone activation marker H3K9ac, which is a deacetylation target of HDAC3 [34], was found to be decreased in the Claudin-5 promoter under HG stimulation, consistent with our previous study [10]. Therefore, HG conditions may provoke HDAC3 to reduce the amount of H3K9ac bound to the Claudin-5 promoter, suppressing its transcription. However, an effective therapy for claudin-5 insufficiency and cardiac microvascular hyperpermeability in individuals with diabetes is lacking.
Recently, BHB was found to have unique protective effects on the cardiovascular system [35, 36]. The injured heart relies more heavily on ketone bodies as an energy source [19, 37]. BHB, which can be produced via the practice of intermittent fasting or administrated directly, is believed to improve cardiovascular function and extend healthspan [16, 38,39,40]. Besides being an energy source, BHB prevents endothelial cell senescence [20, 21]. Even in diabetes, the administration of BHB is reported to alleviate retinopathy and nephropathy [41, 42]. Based on our serial investigations [22, 23], this study found that BHB could promote claudin-5 generation and antagonise diabetes-associated cardiac microvascular hyperpermeability in vivo and in vitro. Clinical studies have proved that oral administration of BHB has beneficial effects for participants, indicating its potential clinical application [43,44,45]. Usually, a 2 mmol/l threshold concentration of BHB is required for its effective treatment [17], which was also confirmed by our data. The results from this study may provide important evidence for extended applications of BHB. Although BHB is reportedly helpful for glucose control in individuals with obesity [45], our data showed no effect of BHB on blood glucose in diabetic rats, which may be attributed to our use of the STZ-induced type 1 diabetes model. Therefore, the potential effects of BHB on blood glucose should be further investigated in type 2 diabetes models.
Several mechanisms have been proposed for the protective effects of BHB [18, 20, 24, 25]. It is reported that BHB could modulate functions of transcriptional factors to exert anti-inflammatory actions [46]. In this study, however, BHB did not exhibit any effect on β-catenin indicators. Notably, BHB has been reported to be an inhibitor of HDACs, to activate gene transcription and play protective roles [47, 48]. We found that BHB inhibited HG-induced HDAC3 from binding to the Claudin-5 promoter and β-catenin. HDAC3 inhibition has been shown to prevent blood–brain barrier permeability through activation of nuclear factor erythroid 2–related factor 2 (Nrf2) in male type 2 diabetes mouse models [49]. Our results manifested that BHB inhibited the activity of the key controller, HDAC3, to promote claudin-5 generation in HG-stimulated HCMECs.
Using mass spectrometry analysis of histone acetylation, we identified specific presence of H3K14ac in the Claudin-5 promoter under treatment with BHB. The changes in H3K9ac and H3K14ac, which are the most significant sites for acetylation, vary under different conditions [50]. In this study, HG provoked HDAC3 and reduced H3K9ac in the Claudin-5 promoter, suppressing claudin-5 expression. However, BHB markedly inhibited HDAC3, causing a specific increase in H3K14ac in the Claudin-5 promoter, regardless of the presence of HG. These results hinted at a general mechanism of BHB inhibition of HDAC3 to promote claudin-5-mediated attenuation of endothelial hyperpermeability, contributing to our understanding of the cardiovascular protective effects of BHB. However, the underlying mechanism for the regulation of H3K9ac and H3K14ac requires further clarification.
In conclusion, these data demonstrated that HG stimulation provoked the binding of HDAC3 to the Claudin-5 promoter and β-catenin to reduce H3K9ac levels, suppressing Claudin-5 transcription and triggering cardiac microvascular hyperpermeability; BHB treatment inhibited HDAC3 and caused a specific increase in H3K14ac levels in the Claudin-5 promoter, to ‘turn on’ claudin-5 generation and attenuate diabetic cardiac microvascular hyperpermeability (Fig. 9). These data may provide important evidence for the cardiovascular protective effects of BHB, facilitating its clinical application.
Data availability
Data are available on request from the authors.
Abbreviations
- BHB:
-
β-Hydroxybutyrate
- BHB1:
-
Diabetes mellitus+low concentration BHB group
- BHB2:
-
Diabetes mellitus+intermediate concentration BHB group
- BHB3:
-
Diabetes mellitus+high concentration BHB group
- ChIP:
-
Chromatin immunoprecipitation
- Co-IP:
-
Co-immunoprecipitation
- DM:
-
Diabetes mellitus (group)
- HCMEC:
-
Human cardiac microvascular endothelial cell
- HDAC:
-
Histone deacetylase
- HG:
-
High glucose
- l-HG:
-
High l-glucose
- H3K9ac:
-
Acetylated H3K9
- H3K14ac:
-
Acetylated H3K14
- LG:
-
Low glucose
- STZ:
-
Streptozotocin
- TRITC:
-
Tetramethylrhodamine
References
Dal Canto E, Ceriello A, Rydén L et al (2019) Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 26(2_suppl):25–32. https://doi.org/10.1177/2047487319878371
Liu YL, Zhou XY, Xuan LJ (2019) Magnesium lithospermate B ameliorates microcirculation perfusion in rats by promoting vascular NO production via activating the PI3K/AKT pathway. Acta Pharmacol Sin 40(8):1010–1018. https://doi.org/10.1038/s41401-018-0203-7
Inzucchi SE, Viscoli CM, Young L et al (2019) Diabetes prevention and cardiovascular complications. Diabetologia 62(11):2161–2162. https://doi.org/10.1007/s00125-019-04999-3
Garcia-Vaz E, McNeilly AD, Berglund LM et al (2020) Inhibition of NFAT signaling restores microvascular endothelial function in diabetic mice. Diabetes 69(3):424–435. https://doi.org/10.2337/db18-0870
Cong X, Kong W (2020) Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease. Cell Signal 66:109485. https://doi.org/10.1016/j.cellsig.2019.109485
Li XX, Ling SK, Hu MY, Ma Y, Li Y, Huang PL (2019) Protective effects of acarbose against vascular endothelial dysfunction through inhibiting Nox4/NLRP3 inflammasome pathway in diabetic rats. Free Radic Biol Med 145:175–186. https://doi.org/10.1016/j.freeradbiomed.2019.09.015
Juni RP, Kuster DWD, Goebel M et al (2019) Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by empagliflozin. JACC Basic Transl Sci 4(5):575–591. https://doi.org/10.1016/j.jacbts.2019.04.003
Greene C, Hanley N, Campbell M (2019) Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS 16(1):3. https://doi.org/10.1186/s12987-019-0123-z
Arima M, Nakao S, Yamaguchi M et al (2020) Claudin-5 redistribution induced by inflammation leads to anti-VEGF-resistant diabetic macular edema. Diabetes 69(5):981–999. https://doi.org/10.2337/db19-1121
Li B, Li Y, Liu K et al (2017) High glucose decreases claudins-5 and -11 in cardiac microvascular endothelial cells: antagonistic effects of tongxinluo. Endocr Res 42(1):15–21. https://doi.org/10.3109/07435800.2016.1163723
Tran KA, Zhang X, Predescu D et al (2016) Endothelial β-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis. Circulation 133(2):177–186. https://doi.org/10.1161/CIRCULATIONAHA.115.015982
Morini MF, Giampietro C, Corada M et al (2018) VE-cadherin-mediated epigenetic regulation of endothelial gene expression. Circ Res 122(2):231–245. https://doi.org/10.1161/CIRCRESAHA.117.312392
Rai R, Sun T, Ramirez V et al (2019) Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis. J Cell Mol Med 23(4):3026–3031. https://doi.org/10.1111/jcmm.14162
Zhao TC, Wang Z, Zhao TY (2020) The important role of histone deacetylases in modulating vascular physiology and arteriosclerosis. Atherosclerosis 303:36–42. https://doi.org/10.1016/j.atherosclerosis.2020.04.020
Emmett MJ, Lazar MA (2019) Integrative regulation of physiology by histone deacetylase 3. Nat Rev Mol Cell Biol 20(2):102–115. https://doi.org/10.1038/s41580-018-0076-0
Stekovic S, Hofer SJ, Tripolt N et al (2019) Alternate day fasting improves physiological and molecular markers of aging in healthy, non-obese humans. Cell Metab 30(3):462–476. https://doi.org/10.1016/j.cmet.2019.07.016
Margolis LM, O’Fallon KS (2020) Utility of ketone supplementation to enhance physical performance: a systematic review. Adv Nutr 11(2):412–419. https://doi.org/10.1093/advances/nmz104
Newman JC, Verdin E (2017) β-Hydroxybutyrate: a signaling metabolite. Annu Rev Nutr 37(1):51–76. https://doi.org/10.1146/annurev-nutr-071816-064916
Mizuno Y, Harada E, Nakagawa H et al (2017) The diabetic heart utilizes ketone bodies as an energy source. Metabolism 77:65–72. https://doi.org/10.1016/j.metabol.2017.08.005
Han YM, Bedarida T, Ding Y et al (2018) β-Hydroxybutyrate prevents vascular senescence through hnRNP A1-mediated upregulation of Oct4. Mol Cell 71(6):1064–1078. https://doi.org/10.1016/j.molcel.2018.07.036
Arildsen L, Andersen JV, Waagepetersen HS, Nissen JBD, Sheykhzade M (2019) Hypermetabolism and impaired endothelium-dependent vasodilation in mesenteric arteries of type 2 diabetes mellitus db/db mice. Diab Vasc Dis Res 16(6):539–548. https://doi.org/10.1177/1479164119865885
Wu X, Miao D, Liu Z et al (2020) β-Hydroxybutyrate antagonizes aortic endothelial injury by promoting generation of VEGF in diabetic rats. Tissue Cell 64:101345. https://doi.org/10.1016/j.tice.2020.101345
Luo W, Yu Y, Wang H et al (2020) Up-regulation of MMP-2 by histone H3K9 β-hydroxybutyrylation to antagonize glomerulosclerosis in diabetic rat. Acta Diabetol https://doi.org/10.1007/s00592-020-01552-2
Miyamoto J, Ohue-Kitano R, Mukouyama H et al (2019) Ketone body receptor GPR43 regulates lipid metabolism under ketogenic conditions. Proc Natl Acad Sci U S A 116(47):23813–23821. https://doi.org/10.1073/pnas.1912573116
Neudorf H, Durrer C, Myette-Cote E, Makins C, O’Malley T, Little JP (2019) Oral ketone supplementation acutely increases markers of NLRP3 inflammasome activation in human monocytes. Mol Nutr Food Res 63(11):e1801171. https://doi.org/10.1002/mnfr.201801171
Rojas-Morales P, Pedraza-Chaverri J, Tapia E (2020) Ketone bodies, stress response, and redox homeostasis. Redox Biol 29:101395. https://doi.org/10.1016/j.redox.2019.101395
Li Y, Li X, He K et al (2018) C-peptide prevents NF-κB from recruiting p300 and binding to the inos promoter in diabetic nephropathy. FASEB J 32(4):2269–2279. https://doi.org/10.1096/fj.201700891R
Natarajan R, Northrop N, Yamamoto B (2017) Fluorescein isothiocyanate (FITC)-dextran extravasation as a measure of blood-brain barrier permeability. Curr Protoc Neurosci 79:9.58.1–9.58.15. https://doi.org/10.1002/cpns.25
Gamrat A, Surdacki MA, Chyrchel B, Surdacki A (2020) Endothelial dysfunction: a contributor to adverse cardiovascular remodeling and heart failure development in type 2 diabetes beyond accelerated atherogenesis. J Clin Med 9(7):E2090. https://doi.org/10.3390/jcm9072090
Mordi IR, Tee A, Palmer CN, McCrimmon RJ, Doney ASF, Lang CC (2020) Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes. ESC Heart Fail 7(3):1168–1177. https://doi.org/10.1002/ehf2.12669
Cheung N, Wang JJ, Rogers SL et al (2008) Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol 51(16):1573–1578. https://doi.org/10.1016/j.jacc.2007.11.076
Rom S, Heldt NA, Gajghate S, Seliga A, Reichenbach NL, Persidsky Y (2020) Hyperglycemia and advanced glycation end products disrupt BBB and promote occludin and claudin-5 protein secretion on extracellular microvesicles. Sci Rep 10(1):7274. https://doi.org/10.1038/s41598-020-64349-x
Zhang L, Chen Y, Jiang Q, Song W, Zhang L (2019) Therapeutic potential of selective histone deacetylase 3 inhibition. Eur J Med Chem 162:534–542. https://doi.org/10.1016/j.ejmech.2018.10.072
Ji H, Zhou Y, Zhuang X et al (2019) HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res 79(14):3676–3688. https://doi.org/10.1158/0008-5472.CAN-18-3767
Abdul Kadir A, Clarke K, Evans RD (2020) Cardiac ketone body metabolism. Biochim Biophys Acta Mol basis Dis 1866(6):165739. https://doi.org/10.1016/j.bbadis.2020.165739
Place DE, Kanneganti TD (2019) Fueling ketone metabolism quenches salt-induced hypertension. Trends Endocrinol Metab 30(3):145–147. https://doi.org/10.1016/j.tem.2019.01.004
Horton JL, Davidson MT, Kurishima C et al (2019) The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense. JCI Insight 4(4):e124079. https://doi.org/10.1172/jci.insight.124079
Han YM, Ramprasath T, Zou MH (2020) β-Hydroxybutyrate and its metabolic effects on age-associated pathology. Exp Mol Med 52(4):548–555. https://doi.org/10.1038/s12276-020-0415-z
Nielsen R, Møller N, Gormsen LC et al (2019) Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation 139(18):2129–2141. https://doi.org/10.1161/CIRCULATIONAHA.118.036459
Soto-Mota A, Norwitz NG, Clarke K (2020) Why a d-β-hydroxybutyrate monoester? Biochem Soc Trans 48(1):51–59. https://doi.org/10.1042/BST20190240
Trotta MC, Maisto R, Guida F et al (2019) The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome. PLoS One 14(1):e0211005. https://doi.org/10.1371/journal.pone.0211005
Kimura Y, Kuno A, Tanno M et al (2019) Canagliflozin, a sodium-glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. J Diabetes Investig 10(4):933–946. https://doi.org/10.1111/jdi.13009
Stubbs BJ, Cox PJ, Evans RD et al (2017) On the metabolism of exogenous ketones in humans. Front Physiol 8:848. https://doi.org/10.3389/fphys.2017.00848
Soto-Mota A, Vansant H, Evans RD, Clarke K (2019) Safety and tolerability of sustained exogenous ketosis using ketone monoester drinks for 28 days in healthy adults. Regul Toxicol Pharmacol 109:104506. https://doi.org/10.1016/j.yrtph.2019.104506
Myette-Côté É, Caldwell HG, Ainslie PN, Clarke K, Little JP (2019) A ketone monoester drink reduces the glycemic response to an oral glucose challenge in individuals with obesity: a randomized trial. Am J Clin Nutr 110(6):1491–1501. https://doi.org/10.1093/ajcn/nqz232
Kim DH, Park MH, Ha S et al (2019) Anti-inflammatory action of β-hydroxybutyrate via modulation of PGC-1α and FoxO1, mimicking calorie restriction. Aging 11(4):1283–1304. https://doi.org/10.18632/aging.101838
Cheng CW, Biton M, Haber AL et al (2019) Ketone body signaling mediates intestinal stem cell homeostasis and adaptation to diet. Cell 178(5):1115–1131. https://doi.org/10.1016/j.cell.2019.07.048
Li X, Zhan Z, Zhang J, Zhou F, An L (2020) β-Hydroxybutyrate ameliorates Aβ-induced downregulation of TrkA expression by inhibiting HDAC1/3 in SH-SY5Y cells. Am J Alzheimers Dis Other Dement 35:1533317519883496. https://doi.org/10.1177/1533317519883496
Zhao Q, Zhang F, Yu Z et al (2019) HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice. J Neuroinflammation 16(1):103. https://doi.org/10.1186/s12974-019-1495-3
Jarmasz JS, Stirton H, Davie JR, Del Bigio MR (2019) DNA methylation and histone post-translational modification stability in post-mortem brain tissue. Clin Epigenetics 11(1):5. https://doi.org/10.1186/s13148-018-0596-7
Acknowledgements
The authors thank H. Zhang (Department of Research Platform, Hebei Medical University, Hebei, China) for excellent technical support, Jingjie PTM Biolab Co. Ltd. (Hangzhou, China) for the performance of mass spectrometry, and M. Kahmeyer-Gabbe, (Liwen Bianji, Edanz Editing China; www.liwenbianji.cn/ac) for English editing.
Authors’ relationships and activities
The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Funding
This study was supported by grants from the National Natural Science Foundation of China (81600384 and 81470595) and the Hebei Natural Science Foundation (H2020206386 and H2020206328).
Author information
Authors and Affiliations
Contributions
YL and JQ conceived and designed the project. BL, YY and KL conducted the cell experiments and analysed data. YZ, QG and FZ performed animal experiments. BL, YY, KL and YL interpreted the results. YL and JQ wrote the manuscript. BL, YY and KL contributed equally to this work. All authors contributed to editing the article and approved the final version to be published. YL and JQ are the guarantors of this work.
Corresponding authors
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM
(PDF 491 kb)
Rights and permissions
About this article
Cite this article
Li, B., Yu, Y., Liu, K. et al. β-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes. Diabetologia 64, 226–239 (2021). https://doi.org/10.1007/s00125-020-05305-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-020-05305-2